Rain Oncology Inc. Common Stock
RAIN
RAIN was delisted on the 25th of January, 2024.
59 hedge funds and large institutions have $184M invested in Rain Oncology Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 21 increasing their positions, 10 reducing their positions, and 2 closing their positions.
750% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 2
110% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 10
28% more funds holding
Funds holding: 46 → 59 (+13)
7% more capital invested
Capital invested by funds: $172M → $184M (+$12.7M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7.03% less ownership
Funds ownership: 86.49% → 79.46% (-7%)
41% less call options, than puts
Call options by funds: $720K | Put options by funds: $1.23M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$13.4M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$4.31M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.96M |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$2.31M |
| 5 |
GC
GMT Capital
Atlanta,
Georgia
|
+$1.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$23.7M |
| 2 |
PA
Perceptive Advisors
New York
|
-$7.72M |
| 3 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$2.62M |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$2.16M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$1.25M |
RAIN Hedge Fund Activity: Q1 2023 in Review
59 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Rain Oncology Inc. Common Stock (RAIN) for Q1 2023, worth a combined $184M — up 7.4% from $172M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new RAIN positions and 2 closed out — a net gain of 15 holders — while 21 added to existing stakes and 10 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $13.4M. The largest seller was Deerfield Management, cutting an estimated $23.7M.
- 59 institutional investors held Rain Oncology Inc. Common Stock (RAIN) as of Q1 2023, up from 46 in Q4 2022.
- Funds reported $184M of Rain Oncology Inc. Common Stock stock for Q1 2023, up 7.4% quarter-over-quarter.
- 17 funds opened new Rain Oncology Inc. Common Stock positions in Q1 2023 and 2 closed out, a net change of +15 holders.
- The largest Rain Oncology Inc. Common Stock buyer in Q1 2023 was Adage Capital Partners, an estimated $13.4M added.
- The largest Rain Oncology Inc. Common Stock seller in Q1 2023 was Deerfield Management, an estimated $23.7M sold.
Based on aggregated 13F filings for Q1 2023.